ArticleThe clinical respiratory journal2022
Overprescription of short-acting β
Article in The clinical respiratory journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 8 citations in OpenAlex.
- Saudi expert consensus on the management of acute asthma and COPD exacerbations with algorithm of aerosol drug delivery device recommendations.International journal of emergency medicine · 2026Article
- Characteristics of Patients with Severe Uncontrolled Asthma in Saudi Arabia: A Cross-Sectional Study.Journal of asthma and allergy · 2026Article
- The digital gatekeeper: a practical operational framework for differentiating pseudo-severe from severe asthma.Frontiers in medicine · 2026Article
- The Feasibility and Impact of Implementing Interventions to Reduce Short-Acting βAdvances in therapy · 2025Review
- Over-the-Counter Bronchodilators Use Among Asthmatic Patients in Al-Medina Al-Monawwara.Cureus · 2024Article
- Over-the-counter use of short-acting beta-2 agonists: a systematic review.Journal of pharmaceutical policy and practice · 2023Review
- Evaluation of short-acting Beta-2-agonist prescriptions and associated clinical outcomes: Findings from the SABA use IN Asthma (SABINA) study in Asia.The World Allergy Organization journal · 2023Article
- Overprescription of short-acting βThe clinical respiratory journal · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 3 countries.
Funding
Abstract
Despite near-universal health care and timely updates to treatment guidelines in Saudi Arabia, asthma control remains suboptimal, warranting deeper exploration of its management practices. This study describes asthma characteristics and prescription patterns of short-acting β
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.